首页9VC • ETR
add
ATAI Life Sciences NV
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
收入 | -5000.00 | -127.78% |
经营支出 | 2934.10万 | -12.62% |
净收入 | -3895.80万 | -112.98% |
净利润率 | 77.92万 | 866.72% |
每股收益 | -0.24 | -100.00% |
息税折旧摊销前利润 | -2912.10万 | 12.97% |
有效税率 | 1.81% | — |
资产负债表
总资产
负债总额
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 6233.00万 | -65.23% |
总资产 | 1.59亿 | -45.69% |
负债总额 | 4283.30万 | -12.87% |
权益总额 | 1.17亿 | — |
发行在外的股份 | 1.98亿 | — |
市净率 | 1.91 | — |
资产回报率 | -41.11% | — |
资本回报率 | -46.44% | — |
现金流
现金净变动
| (USD) | 2024年12月info | 年同比变化 |
|---|---|---|
净收入 | -3895.80万 | -112.98% |
来自运营的现金 | -2429.50万 | -10.62% |
投资现金 | 656.00万 | 897.08% |
融资现金 | 15.40万 | 101.82% |
现金净变动 | -1745.80万 | 44.50% |
自由现金流 | -172.12万 | 86.74% |
简介
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
CEO
成立时间
2018
网站
员工数量
54
